Harrow Inc
HROW at a Glance
- Market cap
- $1.1B
- Revenue (TTM)
- $303.3M
- Profit margin
- -9.4%
- EPS (TTM)
- $-0.81
- 52-week range
- $26 – $55
- Street target
- $62.25
Headquartered in Nashville, TN Fiscal year ends December NASDAQ: HROW harrow.com
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a North American ophthalmic pharmaceutical company. It sells a broad portfolio of branded, generic, OTC and compounded eye-care products addressing front- and back-of-the-eye conditions, including dry eye disease, wet age-related macular degeneration, cataract surgery, glaucoma and ocular surface and retina diseases.
Key branded products:
- VEVYE, a water-free cyclosporine for dry eye disease and its largest product
- IHEEZO, a chloroprocaine ocular anesthetic gel
- TRIESENCE, a preservative-free injectable triamcinolone
- BYOOVIZ, a LUCENTIS biosimilar launched in July 2026
- TYRVAYA, a varenicline nasal spray for dry eye acquired in October 2026
- VERKAZIA, NATACYN, IOPIDINE, VIGAMOX, MAXIDEX, NEVANAC, ILEVRO, TOBRADEX ST, MAXITROL, FLAREX, ZERVIATE and FRESHKOTE PF
Harrow also runs a compounding business. It sells through four commercial teams (Ocular Surface Disease, Retina, Surgical and Access+ for compounded products). The HarrowRx platform routes prescriptions and buy-and-bill orders to pharmacy and distribution partners.
Pipeline:
- OPUVIZ, an EYLEA biosimilar planned for a 2027 launch
- G-MELT, a sublingual midazolam/ketamine for cataract-surgery sedation, with an NDA expected by end of 2026
- YOCHIL, a pediatric midazolam ODT
- H-N08, a next-generation TRIESENCE
- CR-01, a conjunctival drug-delivery device for ocular cancer
- BYQLOVI, a clobetasol product
Branded products generated about 84% of Q3 2026 revenue. Updated
Frequently Asked Questions
What does Harrow do?
Harrow, Inc. (Nasdaq: HROW) is a North American ophthalmic pharmaceutical company.
What is the HROW stock price target?
The Wall Street consensus 12-month price target for HROW is $62.25.